Last 7 days
-2.2%
Last 30 days
-3.2%
Last 90 days
-2.8%
Trailing 12 Months
8.5%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 298.0B | 1.4B | -3.25% | 8.54% | -148.7 | 210.43 | 20.37% | -37.45% |
ABBV | 279.9B | 58.1B | 4.88% | 1.38% | 23.64 | 4.82 | 3.30% | 2.55% |
REGN | 87.7B | 12.2B | 9.61% | 20.63% | 20.21 | 7.2 | -24.26% | -46.28% |
VRTX | 80.8B | 8.9B | 6.80% | 24.91% | 24.32 | 9.05 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -5.53% | 16.05% | -20.81 | 22.69 | 22.88% | -32.64% |
SRPT | 11.5B | 933.0M | 2.93% | 61.85% | -16.28 | 12.27 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -9.77% | 22.96% | 13.92 | 5.23 | 14.88% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.2B | 504.0K | -19.59% | 144.55% | -14.38 | 2.5K | -66.53% | -22.12% |
RARE | 2.6B | 363.3M | -18.37% | -45.49% | -3.74 | 7.28 | 3.39% | -55.81% |
BPMC | 2.6B | 204.0M | 1.49% | -34.21% | -4.68 | 12.78 | 13.30% | 13.44% |
MRTX | 2.3B | 12.4M | -15.06% | -52.42% | -3.05 | 181.9 | - | -27.34% |
SMALL-CAP | ||||||||
CPRX | 1.7B | 214.2M | 4.81% | 93.98% | 20.42 | 7.92 | 52.10% | 110.42% |
MGNX | 412.2M | 151.9M | 1.98% | -27.23% | -3.44 | 2.71 | 96.19% | 40.75% |
CRBP | 28.6M | - | 145.52% | 1270.00% | -0.67 | 19.11 | -77.61% | 7.22% |
CYTK | 3.1M | 94.6M | -20.08% | -11.44% | -0.01 | 0.03 | 34.30% | -80.65% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 13.3% | 1,415,921,000 | 1,249,805,000 | 1,068,617,000 | 877,037,000 | 1,176,283,000 |
S&GA Expenses | 1.8% | 1,277,852,000 | 1,255,369,000 | 1,201,704,000 | 1,102,590,000 | 990,123,000 |
R&D Expenses | 1.0% | 1,640,508,000 | 1,624,970,000 | 1,550,544,000 | 1,528,428,000 | 1,459,239,000 |
EBITDA | 9.1% | -1,842,279,000 | -2,025,714,000 | -1,926,567,000 | -1,870,492,000 | - |
EBITDA Margin | 19.7% | -1.30 | -1.62 | -1.80 | -2.13 | - |
Earnings Before Taxes | 7.4% | -1,961,037,000 | -2,116,876,000 | -1,998,716,000 | -1,921,702,000 | -1,438,588,000 |
EBT Margin | 18.2% | -1.38 | -1.69 | -1.87 | -2.19 | - |
Interest Expenses | 76.2% | 52,480,000 | 29,779,000 | 14,790,000 | -1,507,000 | -15,757,000 |
Net Income | 6.8% | -2,003,815,000 | -2,149,158,000 | -2,029,716,000 | -1,948,594,000 | -1,457,816,000 |
Net Income Margin | 17.7% | -1.42 | -1.72 | -1.86 | -2.18 | - |
Free Cahsflow | 9.1% | -1,822,053,000 | -2,005,322,000 | -1,897,517,000 | -1,926,065,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -5.2% | 6,379 | 6,726 | 7,378 | 8,021 | 8,536 |
Current Assets | -9.4% | 5,207 | 5,749 | 6,346 | 6,948 | 7,614 |
Cash Equivalents | -7.8% | 3,870 | 4,197 | 4,531 | 4,347 | 4,376 |
Inventory | -2.9% | 282 | 291 | 262 | 246 | 243 |
Net PPE | 24.1% | 846 | 682 | 633 | 625 | 588 |
Liabilities | -3.6% | 1,996 | 2,071 | 2,076 | 2,136 | 2,403 |
Current Liabilities | 4.1% | 1,469 | 1,411 | 1,398 | 1,376 | 1,600 |
LT Debt, Current | -25.5% | 329 | 441 | 381 | 407 | 2,725 |
LT Debt, Non Current | 593.3% | 1,443 | 208 | 1,241 | 1,278 | 202 |
Shareholder's Equity | -5.8% | 4,383 | 4,655 | 5,197 | 5,774 | 6,133 |
Retained Earnings | -6.7% | -7,080 | -6,635 | -5,971 | -5,400 | -5,076 |
Additional Paid-In Capital | 0.8% | 11,541 | 11,452 | 11,357 | 11,268 | 11,191 |
Accumulated Depreciation | 5.0% | 150 | 143 | 138 | 124 | - |
Shares Outstanding | 0.5% | 1,356 | 1,350 | 1,350 | 1,335 | 1,335 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 11.2% | -1,496 | -1,686 | -1,620 | -1,660 | -1,298 |
Share Based Compensation | 5.2% | 303 | 288 | 277 | 260 | 241 |
Cashflow From Investing | -6.1% | 1,077 | 1,148 | 966 | 559 | 641 |
Cashflow From Financing | -100.5% | -18.97 | 3,476 | 3,465 | 3,518 | 3,637 |
100%
66.2%
34.6%
Y-axis is the maximum loss one would have experienced if BeiGene was unfortunately bought at previous high price.
34.2%
6.8%
19.3%
FIve years rolling returns for BeiGene.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | BAILLIE GIFFORD & CO | added | 6.19 | 316,951,000 | 749,714,000 | 0.78% |
2023-03-06 | OLD MISSION CAPITAL LLC | new | - | 5,767,270 | 5,767,270 | 0.16% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -0.45 | 74,000 | 193,000 | -% |
2023-02-28 | Voya Investment Management LLC | sold off | -100 | -631,000 | - | -% |
2023-02-24 | National Pension Service | sold off | -100 | -1,288,660 | - | -% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | 100 | 1,100 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 1,980 | 1,980 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 2.31 | 2,119,060 | 5,284,060 | 0.01% |
2023-02-17 | TRUIST FINANCIAL CORP | new | - | 249,852 | 249,852 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | added | 10.34 | 2,038 | 7,038 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | hhlr advisors, ltd. | 10.9% | 147,043,058 | SC 13D/A | |
Feb 13, 2023 | capital international investors | 8.2% | 110,215,170 | SC 13G/A | |
Feb 10, 2023 | oyler john | 5.1% | 70,026,397 | SC 13G/A | |
Aug 16, 2022 | hhlr advisors, ltd. | 10.9% | 147,035,258 | SC 13D/A | |
Feb 14, 2022 | oyler john | 5.1% | 69,558,605 | SC 13G/A | |
Feb 11, 2022 | capital international investors | 7.8% | 104,036,177 | SC 13G/A | |
Feb 11, 2022 | beigene, ltd. | 5.1% | 69,558,605 | SC 13G/A | |
Feb 11, 2022 | invesco ltd. | 5.6% | 39,028,821 | SC 13G | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 16, 2021 | capital international investors | 7.6% | 89,894,623 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.97 -99.56% | 1.20 -99.45% | 1.95 -99.11% | 3.33 -98.48% | 6.11 -97.22% |
Current Inflation | 0.95 -99.57% | 1.15 -99.48% | 1.81 -99.18% | 2.99 -98.64% | 5.35 -97.56% |
Very High Inflation | 0.93 -99.58% | 1.10 -99.50% | 1.64 -99.25% | 2.59 -98.82% | 4.48 -97.96% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 20, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Feb 27, 2023 | 10-K | Annual Report | |
Feb 27, 2023 | 8-K | Current Report | |
Feb 14, 2023 | SC 13D/A | 13D - Major Acquisition | |
Feb 13, 2023 | SC 13G/A | Major Ownership Report | |
Feb 10, 2023 | SC 13G/A | Major Ownership Report | |
Feb 10, 2023 | SC 13G/A | Major Ownership Report | |
Jan 31, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-16 | Wang Xiaodong | gifted | - | - | -67,444 | - |
2023-03-08 | Wang Xiaodong | acquired | 8,792 | 0.13 | 67,635 | - |
2023-03-08 | Wang Xiaodong | sold | -15,287,300 | 226 | -67,635 | - |
2023-03-01 | Wang Julia Aijun | sold | -82,391 | 240 | -343 | chief financial officer |
2023-01-12 | Wang Xiaodong | sold | -1,302,580 | 260 | -5,000 | - |
2023-01-11 | Wang Xiaodong | sold | -631,647 | 252 | -2,500 | - |
2023-01-10 | Wang Xiaodong | sold | -400,152 | 250 | -1,600 | - |
2023-01-10 | OYLER JOHN | sold | -1,689,160 | 248 | -6,797 | chief executive officer |
2023-01-10 | OYLER JOHN | sold | -3,378,290 | 248 | -13,594 | chief executive officer |
2023-01-09 | Wang Xiaodong | sold | -225,000 | 250 | -900 | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues | |||
Total revenues | $ 1,415,921 | $ 1,176,283 | $ 308,874 |
Expenses | |||
Cost of sales - product | 286,475 | 164,906 | 70,657 |
Research and development | 1,640,508 | 1,459,239 | 1,294,877 |
Selling, general and administrative | 1,277,852 | 990,123 | 600,176 |
Amortization of intangible assets | 751 | 750 | 846 |
Total expenses | 3,205,586 | 2,615,018 | 1,966,556 |
Loss from operations | (1,789,665) | (1,438,735) | (1,657,682) |
Interest income (expense), net | 52,480 | (15,757) | 1,998 |
Other (expense) income, net | (223,852) | 15,904 | 37,490 |
Loss before income taxes | (1,961,037) | (1,438,588) | (1,618,194) |
Income tax expense | 42,778 | 19,228 | 10,397 |
Net loss | (2,003,815) | (1,457,816) | (1,628,591) |
Less: net loss attributable to noncontrolling interests | 0 | 0 | (3,617) |
Net loss attributable to BeiGene, Ltd. | $ (2,003,815) | $ (1,457,816) | $ (1,624,974) |
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share) | $ (1.49) | $ (1.21) | $ (1.50) |
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share) | $ (1.49) | $ (1.21) | $ (1.50) |
Weighted-average shares outstanding, basic (in shares) | 1,340,729,572 | 1,206,210,049 | 1,085,131,783 |
Weighted-average shares outstanding, diluted (in shares) | 1,340,729,572 | 1,206,210,049 | 1,085,131,783 |
Net loss per American Depositary Share (ADS), basic (in dollars per share) | $ (19.43) | $ (15.71) | $ (19.47) |
Net loss per American Depositary Share (ADS), diluted (in dollars per share) | $ (19.43) | $ (15.71) | $ (19.47) |
Weighted-average ADSs outstanding, basic (in shares) | 103,133,044 | 92,785,388 | 83,471,676 |
Weighted-average ADSs outstanding, diluted (in shares) | 103,133,044 | 92,785,388 | 83,471,676 |
Product revenue, net | |||
Revenues | |||
Total revenues | $ 1,254,612 | $ 633,987 | $ 308,874 |
Collaboration revenue | |||
Revenues | |||
Total revenues | $ 161,309 | $ 542,296 | $ 0 |
CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,869,564 | $ 4,375,678 |
Short-term restricted cash | 196 | 328 |
Short-term investments | 665,251 | 2,241,962 |
Accounts receivable, net | 173,168 | 483,113 |
Inventories | 282,346 | 242,626 |
Prepaid expenses and other current assets | 216,553 | 270,173 |
Total current assets | 5,207,078 | 7,613,880 |
Long-term restricted cash | 5,277 | 6,881 |
Property, plant and equipment, net | 845,946 | 587,605 |
Operating lease right-of-use assets | 109,960 | 117,431 |
Intangible assets, net | 40,616 | 46,679 |
Other non-current assets | 170,413 | 163,049 |
Total non-current assets | 1,172,212 | 921,645 |
Total assets | 6,379,290 | 8,535,525 |
Current liabilities: | ||
Accounts payable | 294,781 | 262,400 |
Accrued expenses and other payables | 467,352 | 558,055 |
Deferred revenue, current portion | 213,861 | 187,414 |
Tax payable | 25,189 | 21,395 |
Operating lease liabilities, current portion | 24,041 | 21,925 |
Research and development cost share liability, current portion | 114,335 | 120,801 |
Short-term debt | 328,969 | 427,565 |
Total current liabilities | 1,468,528 | 1,599,555 |
Non-current liabilities: | ||
Long-term debt | 209,148 | 202,113 |
Deferred revenue, non-current portion | 42,026 | 220,289 |
Operating lease liabilities, non-current portion | 34,517 | 43,041 |
Deferred tax liabilities | 15,996 | 14,169 |
Research and development cost share liability, non-current portion | 179,625 | 269,561 |
Other long-term liabilities | 46,095 | 54,234 |
Total non-current liabilities | 527,407 | 803,407 |
Total liabilities | 1,995,935 | 2,402,962 |
Commitments and contingencies | ||
Equity: | ||
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,356,140,180 and 1,334,804,281 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 135 | 133 |
Additional paid-in capital | 11,540,979 | 11,191,007 |
Accumulated other comprehensive (loss) income | (77,417) | 17,950 |
Accumulated deficit | (7,080,342) | (5,076,527) |
Total equity | 4,383,355 | 6,132,563 |
Total liabilities and equity | $ 6,379,290 | $ 8,535,525 |